Drug intelligence / Profile preview

AT06A

Development stage: Phase 1
Lead developer: AC Immune
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Peptides
Administration: Subcutaneous

Overview

AT06A is a peptide-based therapeutic vaccine candidate developed to treat hypercholesterolemia and atherosclerosis by inducing an immune response against proprotein convertase subtilisin/kexin type 9 (PCSK9). By generating PCSK9-specific antibodies, the vaccine aims to increase LDL receptor density and enhance clearance of low-density lipoprotein cholesterol (LDLc) from the bloodstream. In phase 1 clinical trials, AT06A was shown to be safe and immunogenic; however, it did not demonstrate significant LDLc-lowering activity compared to placebo. The drug is being developed by AFFiRiS AG as part of their AFFITOPE® platform[1][5][6].

Other names: AFFITOPE AT06A+adjuvantAT06A + adjuvant

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on AT06A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT06A.

Explore the full profile